27808-16-8

Usage

Uses

Used in Organic Synthesis:
4-Methyl-1H-1,2,3-triazole is used as a synthetic intermediate for the production of various organic compounds due to its high reactivity, which facilitates reactions in synthesis processes.
Used in Pharmaceuticals:
4-Methyl-1H-1,2,3-triazole is used as a building block in the development of pharmaceutical drugs, contributing to the creation of new medications with potential therapeutic applications.
Used in Agrochemicals:
4-Methyl-1H-1,2,3-triazole is used as a component in the formulation of agrochemicals, such as pesticides and herbicides, to enhance their effectiveness in agricultural practices.
Used in Chemical Research:
4-Methyl-1H-1,2,3-triazole is used as a research compound in academic and industrial laboratories, allowing scientists to explore its properties and potential applications in various chemical reactions and processes.

InChI:InChI=1/C3H5N3/c1-3-2-4-6-5-3/h2H,1H3,(H,4,5,6)

Upstream product

• 89166-02-9 5-methyl-1H-[1,2,3]triazole-4-carboxylic acid 
• 74-99-7 prop-1-yne 
• 56020-04-3 N'-(1,1-dimethoxypropan-2-ylidene)-4-methylbenzenesulfonohydrazide 
• 1439-36-7 1-triphenylphosphoranylidene-2-propanone 
• 70380-30-2 1‐benzyl‐4‐(bromomethyl)‐1H‐1,2,3‐triazole 

Downstream Products

• 16681-70-2 1H-1,2,3-triazole-4-carboxylic acid 
• 591232-22-3 1-(2-fluoro-4-nitro-phenyl)-4-methyl-[1,2,3]-triazole 
• 27200-07-3 4-methyl-2-(4-nitrophenyl)-2H-1,2,3-triazole 

Relevant academic research and scientific papers

A Scalable Metal-, Azide-, and Halogen-Free Method for the Preparation of Triazoles

A scalable metal-, azide-, and halogen-free method for the synthesis of substituted 1,2,3-triazoles has been developed. The reaction proceeds through a 3-component coupling of α-ketoacetals, tosyl hydrazide, and a primary amine. The reaction shows outstanding functional-group tolerance with respect to both the α-ketoacetal and amine coupling partners, providing access to 4-, 1,4-, 1,5-, and 1,4,5-substituted triazoles in excellent yield. This robust method results in densely functionalised 1,2,3-triazoles that remain challenging to prepare by azide–alkyne cycloaddition (AAC, CuAAC, RuAAC) methods and can be scaled in either batch or flow reactors. Methods for the chemoselective reaction of either aliphatic amines or anilines are also described, revealing some of the potential of this novel and highly versatile transformation.

Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir

The optimization of the 4-methoxy-6-azaindole series of HIV-1 attachment inhibitors (AIs) that originated with 1 to deliver temsavir (3, BMS-626529) is described. The most beneficial increases in potency and pharmacokinetic (PK) properties were attained by incorporating N-linked, sp2-hybridized heteroaryl rings at the 7-position of the heterocyclic nucleus. Compounds that adhered to a coplanarity model afforded targeted antiviral potency, leading to the identification of 3 with characteristics that provided for targeted exposure and PK properties in three preclinical species. However, the physical properties of 3 limited plasma exposure at higher doses, both in preclinical studies and in clinical trials as the result of dissolution- and/or solubility-limited absorption, a deficiency addressed by the preparation of the phosphonooxymethyl prodrug 4 (BMS-663068, fostemsavir). An extended-release formulation of 4 is currently in phase III clinical trials where it has shown promise as part of a drug combination therapy in highly treatment-experienced HIV-1 infected patients.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

NOVEL COMPOUNDS

Disclosed are N-{[(1R,4S,6R)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and their use as pharmaceuticals.

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiv

Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.